Adc Therapeutics SA (ADCT) – Don’t Be So Quick to Call it Dead

Adc Therapeutics SA (NYSE: ADCT) is 136.75% higher on its value in year-to-date trading and has touched a low of $0.36 and a high of $4.60 in the current 52-week trading range. The question becomes, what are the chances the stock will continue to grow shareholders’ wealth in the market. Here’s what analysts think will happen to its price in the coming time. The ADCT stock was last observed hovering at around $4.11 in the last trading session, with the day’s loss setting it -0.18%.

Currently trading at $3.93, the stock is 47.08% and 107.58% above its SMA20 and SMA50 respectively. However, with a daily trading volume of 1.0 million and changing -4.38% at the moment leaves the stock 149.02% off its SMA200. ADCT registered -13.25% loss for a year compared to 6-month gain of 162.00%. The firm has a 50-day simple moving average (SMA 50) of $1.06 and a 200-day simple moving average (SMA200) of -$0.98.

#1 Small-Cap Uranium Stock for Ultra-Fast Gains in 2024

We've uncovered THE ONE small-cap uranium stock that has unearthed a near-surface, high-grade uranium discovery in the Saudi Arabia of Uranium — Canada's prolific Athabasca Basin. Best of all, this small-cap uranium stock is currently flying just below Wall Street's radar… giving you the early-entry opportunity around US$0.30 per share. But that won't last long. Drills are turning right now with results set to be released to the market very, very soon.

Learn all about it in this brand new FREE online report.

The stock witnessed a 89.86% loss in the last 1 month and extending the period to 3 months gives it a 441.92%, and is 9.17% up over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 10.98% over the week and 11.77% over the month.

Adc Therapeutics SA (ADCT) has around 317 employees, a market worth around $316.92M and $122.57M in sales. Profit margin for the company is -145.64%. Distance from 52-week low is 991.95% and -14.57% from its 52-week high. The company has generated returns on investments over the last 12 months (-333.02%).

Adc Therapeutics SA quarterly earnings per share for the current quarter are estimated at -$0.46 with sales reaching $14.98M over the same period.The EPS is expected to shrink by -18.12% this year, but quarterly earnings will post -67.60% year-over-year. Quarterly sales are estimated to shrink -78.50% in year-over-year returns.

52 institutions hold shares in Adc Therapeutics SA (ADCT), with institutional investors hold 77.98% of the company’s shares. The shares outstanding are 80.64M, and float is at 54.60M with Short Float at 6.15%. Institutions hold 50.47% of the Float.

The top institutional shareholder in the company is Redmile Group, LLC with over 14.05 million shares valued at $30.21 million. The investor’s holdings represent 17.42% of the ADCT Shares outstanding. As of Jun 29, 2023, the second largest holder is Prosight Management, Lp with 5.58 million shares valued at $12.01 million to account for 6.92% of the shares outstanding. The other top investors are Sio Capital Management, LLC which holds 4.02 million shares representing 4.99% and valued at over $8.64 million, while Citadel Advisors Llc holds 3.93% of the shares totaling 3.17 million with a market value of $6.82 million.

Adc Therapeutics SA (ADCT): Who are the competitors?

One of the company’s main competitors (and peers) include Eli Lilly & Co. (LLY) that is trading 113.17% up over the past 12 months.AbbVie Inc. (ABBV) lies in the list of competitors of the Adc Therapeutics SA and is 14.96% higher over the same period from ADCTAstraZeneca PLC ADR (AZN) is -7.78% down on the 1-year trading charts.